These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 39354562)
41. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study. Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012 [TBL] [Abstract][Full Text] [Related]
42. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using Borggreve AS; Goense L; van Rossum PSN; Heethuis SE; van Hillegersberg R; Lagendijk JJW; Lam MGEH; van Lier ALHMW; Mook S; Ruurda JP; van Vulpen M; Voncken FEM; Aleman BMP; Bartels-Rutten A; Ma J; Fang P; Musall BC; Lin SH; Meijer GJ Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):998-1009. PubMed ID: 31987972 [TBL] [Abstract][Full Text] [Related]
43. Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma. Lemarignier C; Di Fiore F; Marre C; Hapdey S; Modzelewski R; Gouel P; Michel P; Dubray B; Vera P Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2008-16. PubMed ID: 25037871 [TBL] [Abstract][Full Text] [Related]
44. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma. Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198 [TBL] [Abstract][Full Text] [Related]
45. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy. Onal C; Torun N; Guler OC; Yildirim BA Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030 [TBL] [Abstract][Full Text] [Related]
46. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer. Calais J; Dubray B; Nkhali L; Thureau S; Lemarignier C; Modzelewski R; Gardin I; Di Fiore F; Michel P; Vera P Eur J Nucl Med Mol Imaging; 2015 May; 42(6):858-67. PubMed ID: 25680400 [TBL] [Abstract][Full Text] [Related]
47. The prognostic value of positron emission tomography/computed tomography-based parameters in locally advanced esophageal squamous cell carcinoma treated with chemoradiation therapy. Zhang W; Jia H; Cheng Z; Diao W; Wang Y; Cao B; Kou Y; Wang Q Nucl Med Commun; 2022 Dec; 43(12):1239-1246. PubMed ID: 36345769 [TBL] [Abstract][Full Text] [Related]
48. Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using 18FDG PET/ CT with Standardized Protocol. Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R; Zaman S Asian Pac J Cancer Prev; 2019 Jul; 20(7):2003-2008. PubMed ID: 31350957 [TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of venous invasion and maximum standardized uptake value of Jeon JH; Lee JM; Moon DH; Yang HC; Kim MS; Lee GK; Zo JI Eur J Surg Oncol; 2017 Feb; 43(2):471-477. PubMed ID: 27912930 [TBL] [Abstract][Full Text] [Related]
50. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832 [TBL] [Abstract][Full Text] [Related]
51. Total Lesion Glycolysis Ratio in Positron Emission Tomography/Computed Tomography Images During Neoadjuvant Chemotherapy Can Predict Pathological Tumor Regression Grade and Prognosis in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus. Sonoda A; Yoshida N; Shiraishi S; Horinouchi T; Tokunaga R; Harada K; Iwatsuki M; Nagai Y; Baba Y; Iwagami S; Miyamoto Y; Baba H Ann Surg Oncol; 2021 Jan; 28(1):167-174. PubMed ID: 32588261 [TBL] [Abstract][Full Text] [Related]
52. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Flamen P; Van Cutsem E; Lerut A; Cambier JP; Haustermans K; Bormans G; De Leyn P; Van Raemdonck D; De Wever W; Ectors N; Maes A; Mortelmans L Ann Oncol; 2002 Mar; 13(3):361-8. PubMed ID: 11996465 [TBL] [Abstract][Full Text] [Related]
53. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192 [TBL] [Abstract][Full Text] [Related]
54. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study. Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580 [TBL] [Abstract][Full Text] [Related]
55. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all? Hsu PK; Chien LI; Huang CS; Hsieh CC; Wu YC; Hsu WH; Chou TY Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):460-6. PubMed ID: 23728085 [TBL] [Abstract][Full Text] [Related]
56. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Roedl JB; Halpern EF; Colen RR; Sahani DV; Fischman AJ; Blake MA Mol Imaging Biol; 2009; 11(1):54-60. PubMed ID: 18769974 [TBL] [Abstract][Full Text] [Related]
57. Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer. Vollenbrock SE; Voncken FEM; Lambregts DMJ; Maas M; Donswijk ML; Vegt E; Ter Beek LC; van Dieren JM; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):176-185. PubMed ID: 32572560 [TBL] [Abstract][Full Text] [Related]
58. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576 [TBL] [Abstract][Full Text] [Related]
59. Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. Greally M; Chou JF; Molena D; Rusch VW; Bains MS; Park BJ; Wu AJ; Goodman KA; Kelsen DP; Janjigian YY; Ilson DH; Ku GY J Thorac Oncol; 2019 Mar; 14(3):540-546. PubMed ID: 30391577 [TBL] [Abstract][Full Text] [Related]
60. Practice pattern and risk of not receiving planned surgery after neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma. Hong TH; Kim TH; Lee G; Yun J; Jeon YJ; Lee J; Shin S; Park SY; Cho JH; Choi YS; Shim YM; Sun JM; Oh D; Kim HK Eur J Cardiothorac Surg; 2024 Jul; 66(1):. PubMed ID: 38913852 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]